Barlogie B, Crowley J. Prognostic implications of cumulative dosing in total therapy 3. Blood. 2012;120(16):3383-3385.


Conflict-of-interest disclosure: B.B. has received research funding from Celgene, Novartis. Centocor, Johnson and Johnson, Onyx, and ICON; is a consultant to Celgene, Millenium, and Genzyme; and has received speaking honoraria from Celgene and Millennium. He is a coinventor on patents and patent applications related to the use of GEP in cancer medicine and holds interest in Signal Genetics. The remaining author declares no competing financial interests.